Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 656 clinical trials
Longitudinal Immune-phenotyping of HCC Following MK-3475

Subjects will be followed up for a further 12 months after end of treatment for recurrence and survival. The sub-study is a tumour sample collection study which will provide pre-treatment immune microenvironment data from up to 15 pairs of HCC/adjuvant liver tissue samples.

serum pregnancy test
hepatectomy
aptt
oncolytic virus therapy
anticoagulants
  • 0 views
  • 19 Feb, 2024
A Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of CN1

This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma. This study will provide a basis for further clinical development of CN1.

b-cell lymphoma
solid tumour
lymphoma
  • 0 views
  • 19 Feb, 2024
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.

tumor excision
taxane
cyclophosphamide
cancer
immunomodulators
  • 0 views
  • 19 Feb, 2024
A Patient-centered Continuous and Interdisciplinary Shared Decision Making Approach for Breast Cancer Rehabilitation

Background: Breast cancer rehabilitation has gradually expanded from post-surgery rehabilitation to continuous rehabilitation including prehabilitation between cancer diagnosis and surgical treatment, post-surgery rehabilitation, and return-to-work/return-home interventions.

  • 0 views
  • 19 Feb, 2024
Neoadjuvant mFOLFOXIRI Plus Bevacizumab With Selective Radiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer

The results of TRIBE showed that FOLFOXIRI plus bevacizumab yield a high objective response rate (ORR) (65%), early tumor shrinkage (ETS) (62.7%) and depth of response (DoR) (43.4%) in patients with metastatic colorectal cancer. The investigators were motivated to investigate this triplet-drugs chemotherpay plus bevacizumab both by the possibility of …

incontinence
mri pelvis
folfox regimen
folfoxiri
obstruction
  • 0 views
  • 19 Feb, 2024
Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION)

The SOLUTION trial aims to show the efficacy and safety of performing radical hysterectomy by minimally invasive surgery using an endoscopic stapler in patients with cervical cancer stage IB1 (FIGO staging 2009) and thus to prove that minimally invasive surgery is non-inferior to open surgery.

adenosquamous carcinoma
open surgery
carcinoma
stage ib1 cervical cancer
uterine cervix
  • 0 views
  • 19 Feb, 2024
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally advanced esophageal cancer patients in China. Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.

esophageal cancer
paclitaxel
squamous cell carcinoma of esophagus
shr-1210
cancer
  • 0 views
  • 19 Feb, 2024
Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer

Interventional, randomised, prospective, monocentric study

metastatic breast cancer
ruta graveolens
cancer
rheumatism
stage iv breast cancer
  • 0 views
  • 19 Feb, 2024
A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert AEG

Primary study endpoints: The incidences of early postoperative complications and mortality. The secondary study endpoints:(1) Surgery and oncology indicators ;(2) Early postoperative recovery information ;(3) 3-year disease-free survival and overall survival rate;(4) 5-year disease-free survival and overall survival.

  • 0 views
  • 19 Feb, 2024
CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas

All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor over 9-11 days.

serum pregnancy test
acute infection
glioma
pediatric
anticonvulsants
  • 0 views
  • 19 Feb, 2024